1
|
Siverino C, Fahmy-Garcia S, Mumcuoglu D, Oberwinkler H, Muehlemann M, Mueller T, Farrell E, van Osch GJVM, Nickel J. Site-Directed Immobilization of an Engineered Bone Morphogenetic Protein 2 (BMP2) Variant to Collagen-Based Microspheres Induces Bone Formation In Vivo. Int J Mol Sci 2022; 23:ijms23073928. [PMID: 35409290 PMCID: PMC8999711 DOI: 10.3390/ijms23073928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Revised: 03/21/2022] [Accepted: 03/29/2022] [Indexed: 11/26/2022] Open
Abstract
For the treatment of large bone defects, the commonly used technique of autologous bone grafting presents several drawbacks and limitations. With the discovery of the bone-inducing capabilities of bone morphogenetic protein 2 (BMP2), several delivery techniques were developed and translated to clinical applications. Implantation of scaffolds containing adsorbed BMP2 showed promising results. However, off-label use of this protein-scaffold combination caused severe complications due to an uncontrolled release of the growth factor, which has to be applied in supraphysiological doses in order to induce bone formation. Here, we propose an alternative strategy that focuses on the covalent immobilization of an engineered BMP2 variant to biocompatible scaffolds. The new BMP2 variant harbors an artificial amino acid with a specific functional group, allowing a site-directed covalent scaffold functionalization. The introduced artificial amino acid does not alter BMP2′s bioactivity in vitro. When applied in vivo, the covalently coupled BMP2 variant induces the formation of bone tissue characterized by a structurally different morphology compared to that induced by the same scaffold containing ab-/adsorbed wild-type BMP2. Our results clearly show that this innovative technique comprises translational potential for the development of novel osteoinductive materials, improving safety for patients and reducing costs.
Collapse
Affiliation(s)
- Claudia Siverino
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
| | - Shorouk Fahmy-Garcia
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.F.-G.); (D.M.); (G.J.V.M.v.O.)
- Department of Internal Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands;
| | - Didem Mumcuoglu
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.F.-G.); (D.M.); (G.J.V.M.v.O.)
- Fujifilm Manufacturing Europe B.V., 5047 TK Tilburg, The Netherlands
| | - Heike Oberwinkler
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
| | - Markus Muehlemann
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
| | - Thomas Mueller
- Department for Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, 97082 Wuerzburg, Germany;
| | - Eric Farrell
- Department of Oral and Maxillofacial Surgery, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands;
| | - Gerjo J. V. M. van Osch
- Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands; (S.F.-G.); (D.M.); (G.J.V.M.v.O.)
- Department of Otorhinolaryngology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands
| | - Joachim Nickel
- Department of Tissue Engineering and Regenerative Medicine, University Hospital Wuerzburg, 97070 Wuerzburg, Germany; (C.S.); (H.O.); (M.M.)
- Fraunhofer ISC, Translational Center RT, 97070 Wuerzburg, Germany
- Correspondence: ; Tel.: +49-0931-3184122
| |
Collapse
|
2
|
Posa F, Grab AL, Martin V, Hose D, Seckinger A, Mori G, Vukicevic S, Cavalcanti-Adam EA. Copresentation of BMP-6 and RGD Ligands Enhances Cell Adhesion and BMP-Mediated Signaling. Cells 2019; 8:E1646. [PMID: 31847477 PMCID: PMC6953040 DOI: 10.3390/cells8121646] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 12/09/2019] [Accepted: 12/13/2019] [Indexed: 12/16/2022] Open
Abstract
We report on the covalent immobilization of bone morphogenetic protein 6 (BMP-6) and its co-presentation with integrin ligands on a nanopatterned platform to study cell adhesion and signaling responses which regulate the transdifferentiation of myoblasts into osteogenic cells. To immobilize BMP-6, the heterobifunctional linker MU-NHS is coupled to amine residues of the growth factor; this prevents its internalization while ensuring that its biological activity is maintained. Additionally, to allow cells to adhere to such platform and study signaling events arising from the contact to the surface, we used click-chemistry to immobilize cyclic-RGD carrying an azido group reacting with PEG-alkyne spacers via copper-catalyzed 1,3-dipolar cycloaddition. We show that the copresentation of BMP-6 and RGD favors focal adhesion formation and promotes Smad 1/5/8 phosphorylation. When presented in low amounts, BMP-6 added to culture media of cells adhering to the RGD ligands is less effective than BMP-6 immobilized on the surfaces in inducing Smad complex activation and in inhibiting myotube formation. Our results suggest that a local control of ligand density and cell signaling is crucial for modulating cell response.
Collapse
Affiliation(s)
- Francesca Posa
- Department of Cellular Biophysics, Max Planck Institute for Medical Research, Jahnstr. 29, 69120 Heidelberg, Germany
- Department of Biophysical Chemistry, Institute of Physical Chemistry, Heidelberg University, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany
- Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto, 71122 Foggia, Italy
| | - Anna Luise Grab
- Department of Cellular Biophysics, Max Planck Institute for Medical Research, Jahnstr. 29, 69120 Heidelberg, Germany
- Department of Biophysical Chemistry, Institute of Physical Chemistry, Heidelberg University, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany
- Genome Biology Unit, EMBL, Meyerhofstraße 1, 69117 Heidelberg, Germany
| | - Volker Martin
- Department of Cellular Biophysics, Max Planck Institute for Medical Research, Jahnstr. 29, 69120 Heidelberg, Germany
- Department of Biophysical Chemistry, Institute of Physical Chemistry, Heidelberg University, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany
| | - Dirk Hose
- Laboratory for Myeloma Research and Medical Clinic V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
| | - Anja Seckinger
- Laboratory for Myeloma Research and Medical Clinic V, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
| | - Giorgio Mori
- Department of Clinical and Experimental Medicine, University of Foggia, via L. Pinto, 71122 Foggia, Italy
| | - Slobodan Vukicevic
- Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, School of Medicine, University of Zagreb, Šalata 11, 10000 Zagreb, Croatia
| | - Elisabetta Ada Cavalcanti-Adam
- Department of Cellular Biophysics, Max Planck Institute for Medical Research, Jahnstr. 29, 69120 Heidelberg, Germany
- Department of Biophysical Chemistry, Institute of Physical Chemistry, Heidelberg University, Im Neuenheimer Feld 253, 69120 Heidelberg, Germany
| |
Collapse
|